Fax: (617) 394-2844
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma †‡
Cancer and Leukemia Group B (CALGB) 80003
Article first published online: 23 DEC 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 12, pages 2620–2628, 15 June 2011
How to Cite
Mamon, H. J., Niedzwiecki, D., Hollis, D., Tan, B. R., Mayer, R. J., Tepper, J. E., Goldberg, R. M., Blackstock, A. W., Fuchs, C. S. and for the Cancer and Leukemia Group B (2011), A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma . Cancer, 117: 2620–2628. doi: 10.1002/cncr.25742
We thank Margaret Hall for expert assistance with data analysis.
The following institutions participated in this study: Christiana Care Health Services, Inc. CCOP, Wilmington, Delaware (Stephen Grubbs, MD, supported by CA45418); Dana-Farber Cancer Institute, Boston, Massachusetts (Harold J. Burstein, MD, PhD, supported by CA32291); Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon, New Hampshire (Konstantin Dragnev, MD, supported by CA04326); Georgetown University Medical Center, Washington, DC (Minetta C. Liu, MD, supported by CA77597); Hematology-Oncology Associates of Central New York CCOP, Syracuse, New York (Jeffrey Kirshner, MD, supported by CA45389); Kansas City Community Clinical Oncology Program CCOP, Kansas City, Missouri (Rakesh Gaur, MD); Long Island Jewish Medical Center, Lake Success, New York (Kanti R. Rai, MD, supported by CA35279); Massachusetts General Hospital, Boston, Massachusetts (Jeffrey W. Clark, MD, supported by CA32291); Mount Sinai Medical Center, Miami, Florida (Rogerio C. Lilenbaum, MD, supported by CA45564); New Hampshire Oncology-Hematology PA, Concord, New Hampshire (Douglas J. Weckstein); NorthShore University HealthSystem CCOP, Evanston, Illinois (David L Grinblatt, MD); Roswell Park Cancer Institute, Buffalo, New York (Ellis Levine, MD, supported by CA59518); Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, North Carolina (James N. Atkins, MD, supported by CA45808); The Ohio State University Medical Center, Columbus, Ohio (Clara D. Bloomfield, MD, supported by CA77658); University of California at San Diego, San Diego, California (Barbara A. Parker, MD, supported by CA11789); University of Iowa, Iowa City, Iowa (Daniel A. Vaena, MD, supported by CA47642); University of Minnesota, Minneapolis, Minnesota (Bruce A Peterson, MD, supported by CA16450); University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri (Michael C Perry, MD, supported by CA12046); University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Thomas C. Shea, MD, supported by CA47559); University of Vermont, Burlington, Vermont (Steven M Grunberg, MD, supported by CA77406); Wake Forest University School of Medicine, Winston-Salem, North Carolina (David D Hurd, MD, supported by CA03927); Washington University School of Medicine, St. Louis, Missouri (Nancy Bartlett, MD, supported by CA77440); and Weill Medical College of Cornell University, New York, New York (John Leonard, MD, supported by CA07968).
- Issue published online: 7 JUN 2011
- Article first published online: 23 DEC 2010
- Manuscript Accepted: 8 SEP 2010
- Manuscript Revised: 11 AUG 2010
- Manuscript Received: 9 JUN 2010
- 2A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg. 1979; 189: 205-208.
- 3Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5- fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 1705-1710., , , et al.
- 6Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008; 19: 1592-1599., , , et al.
- 35Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006; 12: 7099-7107., , , et al.
- 40Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 2006; 7: 349-360., , , ,
- 41Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000; 18: 3384-3389., , , et al.
- 49A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005; 62: 1345-1350., , , et al.
- 51Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000; 18: 3384-3389., , , et al.